Studies show that more than two-thirds of aesthetically-oriented consumers are bothered by submental fullness, or “double chin.” And with social media profile images becoming more important than ever, there is interest in looking one’s best.
Submental fullness due to fat beneath the chin can impact a broad range of both men and women and because the condition can be genetic and resistant to diet and exercise. But there’s KYBELLA®, the first and only FDA-approved injectable treatment that is available by prescription only, that has been proven to improve the appearance of moderate to severe fat beneath the chin by physically destroying fat cells in the treatment area. In two pivotal clinical studies for KYBELLA®, reductions in submental fat volume were observed more frequently in the KYBELLA® treated group of 514 patients compared to the placebo group (508 patients) as measured by both clinician and patient ratings. In addition, visual and emotional impacts of submental fat (happy, bothered, self-conscious, embarrassed, looking older or overweight) were evaluated using a 6-question survey and 79% of 1 and 2-grade composite responders reported satisfaction after 12 weeks post final treatment compared with 33.6% of patients who received placebo.
To view the multimedia release go to:
http://www.multivu.com/players/English/7962051-kybella-injectable-double-chin-treatment-campaign/
Ethicon* joins world-renowned experts in bariatric surgery to share the latest breakthroughs in science and innovation that are advancing surgery in the fight against obesity and metabolic diseases during ObesityWeek 2016, the combined annual meeting of the American Society for Metabolic & Bariatric Surgery (ASMBS) and The Obesity Society (TOS). Ethicon will highlight the growing body of research and evidence on the benefits of bariatric surgery, a new sleeve gastrectomy training module on the Touch Surgery app, and its comprehensive portfolio of bariatric surgery products aimed to improve patient outcomes.
“Ethicon’s mission is to lead the way in resolving the burden of obesity for both patients and healthcare systems by expanding access to care and demonstrating the critical value of treatment through research and evidence, while also enabling new technologies,” said Dr. Elliott Fegelman, Therapeutic Area Expert, Metabolics, Johnson & Johnson Innovation.
To view the multimedia release go to:
http://www.multivu.com/players/English/7965651-ethicon-bariatric-surgery-access-obesity-week-2016/
Kaléo, a privately-held pharmaceutical company, today announced the AUVI-Q® (epinephrine injection, USP) Auto-injector will be available by prescription starting February 14th, and announced AUVI-Q AffordAbility, a first-of-its-kind access program for AUVI-Q. Through this new program, patients with commercial insurance, even those with high-deductible plans, will have an out-of-pocket cost of $0. For patients who do not have government or commercial insurance, and have a household income of less than $100,000, AUVI-Q will be available free of charge. In addition, the cash price for AUVI-Q is $360 and will be available to those patients without government or commercial insurance. Each AUVI-Q prescription includes two Auto-injectors and one Trainer for AUVI-Q.
To view the multimedia release go to:
http://www.multivu.com/players/English/7981051-auvi-q-epinephrine-auto-injector-access-and-availability-launch/
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the American Diabetes Association today revealed common challenges affecting the millions of Americans living with type 2 diabetes as part of the program America’s Diabetes Challenge: Get to Your Goals. Last year, award-winning artist Tim McGraw, renowned actress S. Epatha Merkerson and Chef Leticia Moreinos Schwartz called on patients and their loved ones to share their stories – from inspirational successes to daily struggles. Thousands of people from across the country responded, and revealed common challenges like eating healthy, exercising, sticking to a treatment plan and coping with the disease.
“Type 2 diabetes has affected my family, friends and fans, so I’ve learned it can be challenging to manage. It was great to hear from so many people, and I’m impressed by everyone’s dedication to their health,” said McGraw. “The stories we received shed an important light on the similar hardships people in the community face as they work toward achieving their blood sugar goals.”
To view the multimedia release go to:
https://www.multivu.com/players/English/7988751-merck-americas-diabetes-challenge-tim-mcgraw-s-epatha-merkerson-chef-leticia-moreinos-schwartz/
Varian Medical Systems (NYSE: VAR) today is introducing the Halcyon™ system, an entirely new device for cancer treatment. Engineered to revolutionize clinical workflow, Halcyon simplifies and enhances virtually every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT). This new treatment system is designed to expand the availability of high quality cancer care globally and help save the lives of millions more cancer patients.
“The global cancer challenge is enormous,” said Kolleen Kennedy, president of Varian's Oncology Systems business. “It is expected that there will be 24.6 million cancer cases diagnosed annually by 2030, and there is an acute shortage of equipment and trained clinicians. With the innovations in this new technology platform, the system will deliver high quality Halcyon treatments that empower clinicians to care for many more patients. At Varian we are very excited with the introduction of Halcyon to be taking another big step toward advancing cost-effective cancer care worldwide.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8065951-varian-medical-systems-halcyon-cancer-treatment/
Jason’s Deli and The University of Texas MD Anderson Cancer Center proudly introduce the new Salmon Pacifica Salad as part of an ongoing alliance to raise money to help end cancer for patients and families around the world.
Now through April 2018, 50 cents from the sale of every Salmon Pacifica Salad at participating Jason’s Deli restaurants will be donated to MD Anderson to support cancer prevention research and programs.
To view the multimedia release go to:
https://www.multivu.com/players/English/8102251-jasons-deli-md-anderson-cancer-center-salmon-pacifica-salad/
Blink Health, America’s leading prescription drug savings platform, today launched a program to help #TreatType2 diabetes by committing to give away $10 million worth of medication to patients with type-2 diabetes. People living with diabetes who create an account on Blink Health’s website or free mobile app, starting today, will receive a free, one-year supply of the three most commonly prescribed generic medications for type-2 diabetes: metformin, glipizide and pioglitazone. The program will also cover these three medications for existing Blink Health patients who use them.
To view the multimedia release go to:
https://www.multivu.com/players/English/8117451-blink-health-type-2-diabetes-medications/
Leveraging 130 years of knowledge and expertise across the Johnson & Johnson Family of Companies, Johnson & Johnson Medical Devices (JJMD) is proud to launch a new approach to help drive value-based healthcare in hospitals across Europe, Middle East and Africa (EMEA) – CareAdvantage. This is a data-driven, holistic approach in which JJMD partners with hospitals and other healthcare providers to provide a range of benefits, tailored to the customer’s specific needs and priorities.
The healthcare marketplace is changing, with intensifying pressure to meet the ‘triple aim’ of improving outcomes, increasing patient satisfaction and reducing costs. As the focus shifts from volume to value, there is a growing need for new delivery models, resulting in rapid transformation for hospital systems, clinicians and their patients.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8119051-johnson-medical-devices-careadvantage/
The complete solution to managing vaginal dryness and discomfort inside and out is now available to the millions of women changing physically, emotionally and hormonally every day. The maker of #1 doctor recommended Replens™ vaginal moisturizer introduces hormone-free and fragrance-free Replens™ Moisture Restore External Comfort Gel, for soothing relief from external vaginal dryness, in menopause, post-partum, and after a cancer diagnosis.
“Ladies, don’t despair. Vaginal dryness can be a nuisance at any age. It’s one of the most common symptoms of menopause and unfortunately, can worsen over time. Luckily, there are non-hormonal products like Replens,” says Mary Jane Minkin, M.D., Clinical Professor of Obstetrics, Gynecology and Reproductive Sciences at Yale University. “I recommend these products to patients as first line therapies to help relieve internal and external vaginal dryness.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8066251-replens-vaginal-moisture-restore-external-comfort-gel/
In an effort to improve outcomes for patients with some of the deadliest childhood cancers, St. Jude Children’s Research Hospital scientists have created the world’s largest collection of pediatric solid tumor samples, drug-sensitivity data and related information and have made the resource available at no charge to the global scientific community.
St. Jude and the Howard Hughes Medical Institute collaborated to create the resource, known as the Childhood Solid Tumor Network. The work is reported today as an advance online publication in the scientific journal Nature.
“Survival rates for children with recurrent solid tumors have not improved significantly in more than 20 years and remain below 30 percent,” said corresponding author Michael Dyer, Ph.D., chair of the St. Jude Department of Developmental Neurobiology and a Howard Hughes Medical Institute investigator. “This research will change that by promoting scientific collaboration to leverage the efforts of researchers worldwide to advance understanding and ultimately treatment of pediatric solid tumors.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8121952-st-jude-childrens-childhood-solid-tumor-network/
In honor of World Pancreatic Cancer Day on Nov. 16, people around the world will come together to Demand Better in the fight against the world’s toughest cancer, starting with earlier diagnosis. The annual one-day campaign is an initiative of the World Pancreatic Cancer Coalition, which is comprised of more than 60 organizations from 27 countries on six continents.
Every day, more than 1,000 people worldwide will be diagnosed with pancreatic cancer. Of that, an estimated 985 will die from the disease. Additionally, pancreatic cancer has the lowest survival rate among all major cancers, and in nearly every country, it is the only major cancer with a single-digit five-year survival rate (2-9 percent). These stunning figures are not merely statistics, they represent family members, friends and colleagues on every corner of the globe.
“This year, we are turning World Pancreatic Cancer Day from a day of awareness to a day of action,” said Julie Fleshman, JD, MBA, World Pancreatic Cancer Coalition chair. “As we expand our global movement to end pancreatic cancer, we are demanding better for pancreatic cancer patients now and in the future.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8201651-world-pancreatic-cancer-day-demand-better/
The Cancer Effect is the inspiring true story of one woman’s journey with cancer, written to provide hope and healing for patients, survivors, and those who love them. Moving, enlightening, uplifting, and honest. Learn more about this powerful memoir at www.claudiabretzing.com Non-fiction/self help
